Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Post by skibummon Mar 29, 2018 7:48am
201 Views
Post# 27800822

Crescita now selling Pliaglis in U.S.-good news 4 Knight

Crescita now selling Pliaglis in U.S.-good news 4 Knight

Crescita Announces Launch of Pliaglis in U.S.

Canada NewsWire

MISSISSAUGA, ONMarch 29, 2018 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX) ("Crescita" or "the Company"), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms, is pleased to announce that the first shipments of Pliaglis have now been received and the product will be launched by our U.S. licensing partner.

 

In April 2017, Crescita announced that it had entered into a development and commercialization license agreement ("the Agreement") with Taro Pharmaceuticals Inc. ("Taro").  Under the terms of the Agreement, Crescita granted Taro an exclusive license to the rights to sell and distribute Pliaglis in the U.S. market and for a second-generation enhanced version with patent pending (the Enhanced Formulation). 

"The launch of Pliaglis in the U.S. represents a significant milestone for Crescita. We are encouraged by the prospect for sales growth in the U.S. market," said Serge Verreault, President of Crescita.

About Pliaglis
Pliaglis, a lidocaine and tetracaine (7%/7%) formulation, is a U.S. Food and Drug Administration (FDA) approved topical local anesthetic cream that provides safe and effective local dermal anaesthesia on intact skin prior to superficial dermatological procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing and laser-assisted tattoo removal.  This product contains lidocaine and tetracaine and utilizes the proprietary phase-changing topical cream "Peel" technology.  The "Peel" technology consists of a drug containing cream which, once applied to a patient's skin, dries to form a pliable layer that releases drug into the skin.  Following the application period, Pliaglis forms a pliable layer that is removed from the skin allowing the dermatological procedure to be performed with minimal to no pain.

About Taro Pharmaceutical Industries Ltd.
Taro (NYSE: TARO) is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro, please visit the Company's website at www.taro.com.


Bullboard Posts